Actinogen Medical is an ASX-listed biotechnology company developing innovative treatments for Alzheimer’s disease and the cognitive impairment associated with neurodegenerative diseases and metabolic diseases. Actinogen Medical’s lead drug candidate Xanamem has been specifically designed to reduce production of excess cortisol in the brain. Drugs that reduce cortisol in the brain offer a promising new approach to slowing, or even preventing, the cognitive decline associated with Alzheimer’s disease. Xanamem’s novel mechanism of action sets it apart from other Alzheimer’s treatments. It works by blocking the excess production of cortisol - the stress hormone – through the inhibition of the 11β-HSD1 enzyme in the brain. This enzyme is highly concentrated in the hippocampus and frontal cortex, the areas of the brain most affected by Alzheimer’s disease. There is a strong association between chronic stress and excess cortisol that leads to changes in the brain affecting memory, and to the development of amyloid plaques and neural death – all hallmarks of Alzheimer’s disease.
AlzProtect is a biopharmaceutical company that selects leads and develops drug candidates in the field of Neurodegeneration, focusing on Tauopathies. It was Founded by Dr André Delacourte and Pr Patricia Melnyk. The company develops new classes of compounds with novel MOA to bring effective solutions in treating neurodegenerative diseases such as AD, PSP and FTD. AZP2006, the lead product in clinical Phase, has shown robust data and proof of principle in animal studies together with a good safety profile.
Bioasis Technologies Inc. is a CT-based, early development-stage biopharmaceutical company focused on the non-invasive delivery of therapeutics across the blood-brain barrier (BBB) with our disruptive and enabling, best-in-class proprietary xB³ platform technology for the treatment of CNS disorders. Bioasis developing risk-mitigated, wholly-owned programs focused on CNS cancers, orphan and rare, genetic diseases with high unmet medical need where proof-of-concept exists and have the potential for fast track, early approval. Our lead programs utilize established products with proven efficacy and known safety profiles and have the potential to make these previously non-brain penetrant medicines into the new standard of care for CNS disorders. The xB³ peptide has the ability to deliver a diversity of payloads (small molecules, Abs, siRNA, enzymes and other biologics), allowing for robust testing of the platform technology without relying solely on a single modality and is highly partnerable. Bioasis continues to seek strategic relationships with leading biopharmaceutical partners and research institutions to out-license our xB³ platform technology to improve treatments across CNS / oncology space. Our focus is to deliver hope to over 1.25 billion patients worldwide who suffer from hundreds of previously untreatable diseases and disorders of the central nervous system. We know what our scientific advances can mean for patients — a second chance. Bioasis was founded in 2007 and trades on the TSX Venture Exchange under the symbol “BTI” and on the OTCQB under the symbol “BIOAF.”
BrainScope Company, Inc. is a medical neuro-technology company that is pioneering the future of traumatic brain injury (TBI) assessment. The BrainScope® One device, utilizing Electroencephalogram (EEG) technology cleared by the FDA, is the first objective, adjunctive device capable of assessing the full spectrum of mild traumatic brain injury (mTBI/concussion). Its ability to rapidly identify the likelihood of both structural brain injury and functional brain impairment at the point of care offers an opportunity for dramatic improvement to the current treatment path for evaluating mTBI/concussion patients. The benefits could include diversion from the emergency department (ED), a major reduction in unnecessary CT scans, and early intervention for patients with functional injuries, including concussion—contributing to the best possible outcomes in the shortest possible time.
Clarigent Health delivers artificial intelligence and machine learning technology for the early detection of mental health conditions to direct the most appropriate treatment plan for an individual. The results are both quality of life improvement and reduction of cost to the system and the individual.
Cortexyme is a clinical stage biopharmaceutical company pioneering a novel disease-modifying therapeutic approach to treat what we believe to be a key underlying cause of Alzheimer’s and other degenerative diseases. Cortexyme is targeting a specific pathogen found in the brain of Alzheimer’s patients that causes neurodegeneration and other pathology in animal models. Cortexyme’s lead small molecule, COR388, has advanced through preclinical and Phase Ib testing and is currently the subject of a Phase 2/3 clinical trial in mild to moderate Alzheimer’s disease patients.
GeNeuro’s mission is to develop safe and effective treatments against neurological disorders and autoimmune diseases such as multiple sclerosis (MS) and type 1 diabetes (T1D) by neutralizing potential causal factors expressed by human endogenous retroviruses (HERV), which represent 8% of the human DNA. This new approach focused on HERVs is based on more than 25 years of R&D, including 15 within Institut Mérieux and INSERM before the creation of GeNeuro in 2006. GeNeuro's lead drug candidate, temelimab, is a humanized monoclonal antibody targeting the pathogenic protein HERV-W Env to block key neurodegenerative mechanisms of multiple sclerosis, through reducing microglial activation and through the rescue of the myelin repair process, independently of the immune pathways used by existing drugs. GeNeuro’s recent Phase IIb and its extension have shown its impact on key neuroprotection markers known to be linked to disease progression. These results confirm the potential of temelimab to act against disease progression, the largest unmet medical need in MS. This is also the first time that the benefit of a treatment targeting endogenous retrovirus protein has been observed in a clinical trial, opening a field led by GeNeuro to tackle other areas of unmet medical needs such as T1D or amyotrophic lateral sclerosis.
Helius Medical Technologies, Inc. (Helius) is a neurotech company in the medical device industry, focused on neurological wellness. Helius’ origin stems from the early 1990s, and the pioneering work in neuroplasticity at the Tactile Communication and Neurorehabilitation Laboratory (TCNL) at the University of Wisconsin-Madison. This work led to the development of the investigational Portable Neuromodulation Stimulator (PoNSTM), delivering neurostimulation via the tongue which has been shown in clinical studies to improve the effectiveness of physical exercises in people with neurological symptoms from disease or trauma such as mild-to-moderate traumatic brain injury. Sensing the enormous implications of addressing a massive unmet medical need, Helius was formed as a joint venture between the scientists (Yuri Danilov, Mitch Tyler, and Kurt Kaczmarek) and commercialization experts (Philippe Deschamps, Jonathan Sackier, and Montel Williams).
Metys Pharmaceuticals AG is developing MP-101 for the prevention and treatment of sensory symptoms of peripheral neuropathy. No therapy is indicated to treat or prevent chemotherapy-induced symptoms of peripheral neuropathy; these lead to premature interruption of cancer therapy and linger to reduce patients' quality of life and increase health care costs.
We seek Series A investors to finance the Phase 2 clinical trial of MP-101 in this indication. Our development plans have been discussed and agreed with FDA in a face-to-face pre-IND meeting in February this year. MP-101 is an orally active allosteric modulator of spinal and brain glutamate signalling. It is a patent-pending non-racemic mixture of the dimiracetam enantiomers. Metys Pharmaceuticals AG holds exclusive world-wide rights to the existing IND of racemic dimiracetam from two prior independent development efforts, and will use these data to support - without prior clinical or toxicological bridging data - the Phase 2 trial of MP-101.
Metys Pharmaceuticals AG is privately-held Swiss corporation, financed by private seed investors.
Minoryx is a clinical stage biotech company leading the development of new therapies for X-ALD and other Orphan CNS diseases, a group of rare diseases of genetic origin with a high unmet medical need. The company’s leading program, a differentiated PPAR gamma agonist (MIN-102; leriglitazone), is a candidate for X-linked Adrenoleukodystrophy that has successfully completed phase 1 clinical trials, and is now in a pivotal phase 2/3 trial in adult X-linked Adrenoleukodystrophy (X-ALD) patients with Adrenomyeloneuropathy (AMN) and phase 2 trial in Friedreich’s Ataxia (FRDA) . Minoryx harnesses its unique mechanism of action for potential use in X-ALD and FRDA, two genetic diseases characterized by progressive neurological deterioration with no available pharmacological treatment. Minoryx is also working on expanding the use of MIN-102 into other CNS diseases.
Neuroelectrics® is a digital brain health company that innovates at the intersection of neuroscience, physics, machine learning, and hardware. We have developed wireless EEG and tDCS/tACS/tRNS stimulation devices with up to 32 channels, amongst other products encompassing software and research services, with the purpose of monitoring and enhancing brain health.
An Australian based, not-for-profit contract research organisation specialising in neuroscience clinical research. Our superb range of services will ensure we deliver on your projects in a cost-effective and timely way. Areas of expertise include stroke and stroke-related conditions, multiple sclerosis, epilepsy, Parkinson’s disease, spinal cord injuries, Huntington’s disease, neurosurgery, pain, neuromuscular disease and migraine.
Oryzon is a public clinical stage biopharmaceutical company listed on the Madrid stock exchange and a European leader in the development of epigenetics-based therapies. Oryzon has programs in clinical phase: CNS - Vafidemstat (ORY-2001), a dual LSD1-MAOB inhibitor, currently in three Phase IIA: • "ETHERAL": in mild to moderate AD • "REIMAGINE": aggression in adult population with Alzheimer’s Disease (AD), Adult attention deficit hyperactivity disorder (ADHD), Borderline Personality Disorder (BPD), and Autism Spectrum Disorder (ASD) • "SATEEN": in relapse-remitting and secondary progressive forms of MS. Oncology – Iadademstat (ORY-1001), a selective LSD1 inhibitor, currently in two Phase IIA: • "ALICE": in AML • "CLEPSIDRA": in SCLC A third epigenetic compound (ORY-3001), also against LSD1, has completed the preclinical development, for a yet undisclosed non-oncological indication.
ProNeurogen is an early-stage biotech company. It is developing novel drug therapeutics to prevent and treat inflammation-induce brain disorders, including: pain, cognitive impairment, memory loss and dementia. ProNeurogen's novel drug technology is based on R&D conducted at the University of Arizona.
Regenera Pharma is on a mission: to help patients restore the function lost to neurological diseases. We are making great strides in that direction. Our growing scientific evidence shows that our lead drug candidate has regenerative activity and functional recovery benefits.